Precision medicine is what inspired Marcia Fournier to start BIOARRAY. Marcia has over 15 years experience in oncology, drug discovery, biomarkers, and clinical diagnostics. Prior to founding BIOARRAY, Marcia held positions in top Institutions in the US including GlaxoSmithKline, UC Berkeley and Dana-Farber Cancer Institute. Marcia holds a PhD in molecular biology from Federal University of Rio de Janeiro.

Pamela Layton, is a serial entrepreneur with expertise in biologics and diagnostics. Prior to joining BIOARRAY Pamela was founder and CEO of the Parcell Group, taking one of the first pure stem cell products from bench to bedside for spinal fusion surgeries. She holds multiple U.S. and European patents. She serves as member and advisor to multiple innovation organizations including MIT, SBANE Innovation Awards, Launchpad Ventures.

Jim LaFrance, a member of the Board of Directors, is Chairman of the Board of Vermillion (VRML) Inc., and on the Board of publicly traded High Throughput Genomics (HTGM), a next generation sequencing RNA profiling company. Mr. LaFrance has held positions as CEO of Vermillion and Omnyx, a GE Healthcare JV with UPMC. He has also held executive leadership roles at Ventana Medical Systems (acquired by Roche Diagnostics) and Bayer Diagnostics.

Michal is a serial entrepreneur in life sciences, current Executive Director Office of Tech Dev Harvard Medical School. Prior to joining Harvard in 2005, she held a number of positions in R&D and Business Development at Compugen, most recently as VP of Protein Therapeutics, responsible for the business management of the company's emerging drug discovery pipeline. She has a PhD from the Weizmann Institute of Science, and MBA from INSEAD in France.

Don Hardison, a leader in the diagnostics industry, was most recently the President and CEO of Good Start Genetics. Previously he held a number of executive and senior management positions at companies including Laboratory Corporation of America (COO), Exact Sciences (CEO), OnTarget, Inc., Quest Diagnostics Inc. and SmithKline Beecham. He currently sits on the board of HTG Molecular Diagnostics, IQuity, Seventh Sense and BioTheranostics.

Dr. Witney most recently served as President and CEO of Affymetrix, Inc. and engineered the sale of the company to Thermo Fisher. Previous positions include CEO of Dionex Corp., President of Panomics Inc., President of PerkinElmer’s Drug Discovery Tools division and COO/President of Packard BioScience. He is currently Chairman of the Board of Gyros Protein Technologies and holds Board positions for Cerus Corp., Exagen Diagnostics and Rarecyte.